The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.

While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to Scrip on which one stands a better chance of winning.

England’s NICE has given its backing to the use of Regeneron’s Ronapreve, and the UK’s new health security body is now fully up and running.

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.